Product Information

EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $1.1640 per EA under NDC 33342013807. Its NADAC has been published 251 times since Nov 3, 2021.

FDA first approved this application on Sep 13, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB

Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate
$1.1640per EA

Strength

600; 200; 300 mg/1; mg/1; mg/1

NDC

33342013807

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA204287

FDA Approved

9/13/2021

TE Code

AB

On Market Since

9/13/2021

Pharmacological Classes

Cytochrome P450 2B6 Inducers
Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C9 Inhibitors
Cytochrome P450 3A Inducers
Cytochrome P450 3A4 Inhibitors
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Non-Nucleoside Analog
Non-Nucleoside Reverse Transcriptase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Nucleosides
Nucleosides

Price Statistics

The NADAC for EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB has been published 251 times since Nov 3, 2021, and over the history we have for it it has declined 83.5%. The table below summarizes its recorded NADAC range and movement.

Current price$1.1640 per EA
All-time high$7.0703 (Dec 15, 2021)
All-time low$1.1460 (Jul 17, 2024)
52-week high$1.4988
52-week low$1.1634
Median price$1.6592
Average price$2.8452
Largest weekly change-74.7% (Aug 23, 2023)
Weeks tracked251
Tracking sinceNov 3, 2021

Price History

1W

+0.1%

1M

+0.1%

3M

-2.1%

6M

-15.9%

1Y

-22.3%

3Y

-76.9%

5Y

N/A

All

-83.5%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB, manufactured by Macleods Pharmaceuticals Limited, is $1.1640 per EA (NDC 33342013807), effective Aug 19, 2026.

How has the price of EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB changed over time?

Over the history we have for it, the NADAC for EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB has declined 83.5%. It has been tracked across 251 weekly CMS publications since Nov 3, 2021.

What are the highest and lowest recorded NADAC prices for EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB?

Since Nov 3, 2021, the NADAC for EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB has ranged from a low of $1.1460 (Jul 17, 2024) to a high of $7.0703 (Dec 15, 2021), with a median of $1.6592 per EA.

Are there cheaper alternatives to EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB?

3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB in a comparable dosage form, but none are currently priced below it.

Who manufactures EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB?

EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB (NDC 33342013807) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.